ProCE Banner Activity

Transforming Precision NSCLC Care: Educating and Supporting Patients on TROP-2–Targeted ADCs

Slideset

Slides from a live webinar covering the use of TROP-2 antibody–drug conjugates in patients with advanced NSCLC.

Released: October 09, 2024

Expiration: October 08, 2025

Share

Faculty

Edward B. Garon

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Blanca Ledezma

Blanca Ledezma, MSN, NP-AOCNP

Nurse Practitioner III
Division of Hematology/Oncology
UCLA Santa Monica
Santa Monica, California

Denise Rouse

Denise Rouse, MS, PA-C

Physician Assistant
Thoracic Medical Oncology
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois

Provided by

Provided by Partners for Advancing Clinical Education, in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner